Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone

RECURSION PHARMACEUTICALS, INC.

Milestone triggered by initiation of GLP toxicology study on August 25, 2025.
Issued 2,397,023 contingent shares at $5.2148/share, representing $12.5M value.
Shares issued to Rallybio as seller under July 2025 ENPP1 JV acquisition.
Prospectus supplement filed August 29, 2025 to register shares for resale.
Filing amends prior 8-K from July 8, 2025 regarding the original acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.